Denali Therapeutics Inc. (DNLI): Price and Financial Metrics


Denali Therapeutics Inc. (DNLI): $53.10

0.47 (+0.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DNLI POWR Grades


  • Value is the dimension where DNLI ranks best; there it ranks ahead of 72.25% of US stocks.
  • The strongest trend for DNLI is in Momentum, which has been heading down over the past 47 weeks.
  • DNLI ranks lowest in Momentum; there it ranks in the 7th percentile.

DNLI Stock Summary

  • With a price/earnings ratio of 113.89, Denali Therapeutics Inc P/E ratio is greater than that of about 93.05% of stocks in our set with positive earnings.
  • With a price/sales ratio of 17.84, Denali Therapeutics Inc has a higher such ratio than 89.23% of stocks in our set.
  • Revenue growth over the past 12 months for Denali Therapeutics Inc comes in at 1,187.81%, a number that bests 99.04% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Denali Therapeutics Inc, a group of peers worth examining would be BPMC, MRTX, FIXX, DCPH, and TGTX.
  • DNLI's SEC filings can be seen here. And to visit Denali Therapeutics Inc's official web site, go to www.denalitherapeutics.com.

DNLI Valuation Summary

  • DNLI's price/sales ratio is 18.1; this is 59.47% higher than that of the median Healthcare stock.
  • Over the past 45 months, DNLI's EV/EBIT ratio has gone up 127.6.
  • Over the past 45 months, DNLI's price/earnings ratio has gone up 137.5.

Below are key valuation metrics over time for DNLI.

Stock Date P/S P/B P/E EV/EBIT
DNLI 2021-08-31 18.1 6.0 115.7 106.5
DNLI 2021-08-30 18.0 6.0 115.1 105.9
DNLI 2021-08-27 18.1 6.0 115.6 106.4
DNLI 2021-08-26 17.0 5.7 108.8 99.7
DNLI 2021-08-25 17.8 5.9 113.6 104.4
DNLI 2021-08-24 17.8 5.9 113.9 104.8

DNLI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DNLI has a Quality Grade of C, ranking ahead of 69.42% of graded US stocks.
  • DNLI's asset turnover comes in at 0.249 -- ranking 178th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows DNLI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.249 1 0.058
2021-03-31 0.279 1 0.069
2020-12-31 0.334 1 0.102
2020-09-30 0.032 1 -0.411
2020-06-30 0.044 1 -0.416
2020-03-31 0.042 1 -0.401

DNLI Price Target

For more insight on analysts targets of DNLI, see our DNLI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $86.60 Average Broker Recommendation 1.54 (Moderate Buy)

DNLI Stock Price Chart Interactive Chart >

Price chart for DNLI

DNLI Price/Volume Stats

Current price $53.10 52-week high $93.94
Prev. close $52.63 52-week low $33.68
Day low $51.37 Volume 217,665
Day high $53.46 Avg. volume 571,848
50-day MA $55.68 Dividend yield N/A
200-day MA $64.18 Market Cap 6.46B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.


DNLI Latest News Stream


Event/Time News Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

Latest DNLI News From Around the Web

Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.

DelveInsight Estimates a Promising Picture of Pompe Disease Pipeline Landscape in the Coming Years as Key Pharma Companies Bolster Rare Disease Pipeline

Los Angeles, USA, Sept. 15, 2021 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Picture of Pompe Disease Pipeline Landscape in the Coming Years as Key Pharma Companies Bolster Rare Disease Pipeline The Pompe Disease Pipeline is evolving with novel mechanisms of action (MoAs) that will bring positive changes in the disease pipeline landscape. DelveInsight''s Pompe Disease Pipeline Insights '' report offers comprehensive coverage of the emerging Pompe Disease therapeutics landscape in different stages of clinical development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents. The Pompe Disease Pipeline report provides a complete outlook of the clinical trials, colloborations happening in the domain, recent breakthroughs and growth pro...

Benzinga | September 15, 2021

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS

Intrado Digital Media | September 9, 2021

Denali Therapeutics Inc. (DNLI) Up 5.7% Since Last Earnings Report: Can It Continue?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2021

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denalis Transport Vehicle to cross the blood-brain barrier Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denalis Transport Vehicle to cross the blood-brain barrier

Intrado Digital Media | August 26, 2021

8 Best Stocks to Buy According to Billionaire Nicholas J. Pritzker’s Tao Capital

In this article, we will be discussing 8 best stocks to buy according to billionaire Nicholas J. Pritzker based on his hedge fund’s Q1 portfolio. To skip our detailed analysis of Nicholas J. Pritzker’s hedge fund returns, investment philosophy, and history, you can click to skip ahead to 4 Best Stocks to Buy According to […]

Yahoo | August 9, 2021

Read More 'DNLI' Stories Here

DNLI Price Returns

1-mo 2.29%
3-mo -27.98%
6-mo -14.37%
1-year 38.82%
3-year 183.50%
5-year N/A
YTD -36.60%
2020 380.83%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9877 seconds.